Efficacy of leptospiral vaccine (vax-SPIRAL ®) against challenge with strains isolated from leptospirosis epidemic in nicaragua using the hamster as biomodel

Veterinary World

Volumn 5, Issue 1, 2012, Pages 5-12

  Fernández, Luis Alfredo Rosario ^a   Santiesteban, Niurka Batista ^b   Arrebola, Daniel Francisco Arencibia ^b   Abreú, Bárbara Yolanda Valdés ^b   Toruño, Willian Jirón ^c   Duttman, Chistyane ^c  

^a Institute of Pharmacy and Food Science (IFAL UH)   (Cuba)

^b FINLAY INSTITUTE   (Cuba)

^c National Autonomous University of Nicaragua   (Nicaragua)

Author keywords

Biomodel; Endemic disease; Heterologous protection; Leptospira; Natural disaster; Serogroup

Indexed keywords

EID: 84865155324     PISSN: 09728988     EISSN: 22310916     Source Type: Journal    
DOI: 10.5455/vetworld.2012.5-12     Document Type: Article

References (40)

1. Vinetz, J.M. (2001). Leptospirosis. Curr Opin Infect Dis 14(5):527-538.
2. Koizumi, N, and H. Watanabe. (2005). Leptospirosis Vaccine: Past, Present and Future. J Postgrad Med 51(3):210-214.
3. WHO. (2009). National Leptospirosis Surveillance Report Number 17. January-December 2008: WHO/FAO/OIE Collaborating Centre for Reference and Research on Leptospirosis [in line].p.37-49. Available: http://www.health.qld.gov.au/qhcss/documents/lepto/08_annual.pdf; 2009.
4. Schroder, N., J. Eckert, and G. Stubs. (2008). Schumann. Immune responses induced by spirochetal outer membrane lipoproteins and glycolipids. Immunobiology 213:329-340.
5. OPS. (1999). Main infectious illnesses in Central America during 1998, before and after Mitch. Pan American Public Health Journal 6(6):1-30.
6. Barthi, A.R., E.N. Jarlath, J.N. Ricaldi, M.A. Matthias, M.M. Díaz, and M.A. Lovett. (2003). Leptospirosis. Azoonotic disease a global importance. Lancet Infect Dis 3(12):757-771.
7. Haake, D.A. (2000). Spirochaetal lipoproteins and pathogenesis. Microbiology 146:1491-1504.
8. MINSAP. (1998). National Direction of Epidemiology. National Programs of Prevention and Control of the human Leptospirosis (second version). Havana, Cuba. p. 1-95.
9. ®.Antileptos-pirosis trivalent vaccine (canicola copenhageniy mozdok), for use in human. Registration Medicc Sanitary 846. Cubap. 5-18.
10. ®. Trivalent Antileptospirosis Vaccine For Human Use: Research, Development and Impact On The Disease In Cuba. Medicc Review. 2(5):33-41.
11. Lagovkin, E.A. (1990). The improvement of immunobiological preparations against leptospirosis. Microbiol Immunobiol 2:47-51.
12. Adler, B., and M. de la Peña. (2009). Leptospira and Leptospirosis. Vet Microbiol 30:1010-1016.
13. Martínez, R., A. Pérez, M. Quiñones, R. Cruz, A. Álvarez, and M. Armesto. (2004). Effectiveness and security of a vaccine against the human leptospirosis in Cuba. Panamerican Public Health Journal 15:249-255.
14. González, A., Y. Rodríguez, N. Batista, Y. Valdés, and M. González. (2003). Microbiologic characterization of candidates vaccinate strains of Leptospira interrogans Ballum serogroup. Cuban Journal of Tropical Medicine 55(3): 146-152.
15. González, A., Y. Rodríguez, N. Batista, Y Valdés, J.F. Núñez, and M. Mirabal. (2005). Inmunogenicity and protector capacity in hamsters of monovalentes antileptospirosics vaccine of whole cells of Ballum serogroup. Argentina Journal of Microbiol 37(4): 169-175.
16. ® Vaccine. MEDICC Review 10(3):38-42.
17. ®, trivalent vaccine (Canicola-Icterohaemorragiae-Pomona). Protectogenic crossed capacity front of the challenge with L. Ballum of high pathogenicity in the Golden Syrian Hámster model. VacciMonitor 17(2): 14-19.
18. Martínez, R., A. Pérez, M. Baró, M. Álvarez, and J. Menéndez. (2000). Evaluation of the effectiveness of a new vaccine against human leptospirosis in a group of risk. Panamerican Public Health Journal 8(6):385-392.
19. Levett, P.N. (2003). Usefulness of serological analysis as a predictor of the infecting serovar in patients with severe leptospirosis. Clin Infect Dis 36:447-452.
20. Ellinghausen, H.C, and W.G. McCullough. (1965). Nutrition of Leptospira pomona and growth of 13 other serotypes: Fractionation of oleic albumin complex and a medium of bovine albuminand poly sorbate 80. Am J Vet Res 26:45-51.
21. Fletcher, W. (1928). Recent work on leptospirosis, tsutsugamushi disease and tropical typhus in the Federated Malay States. Trans Roy Soc Trop Med Hyg 21:265-282.
22. ® (Antilepto-spirosic Trivalent Vaccine) in hamsters front challenge with virulent Leptospira strains of canicola, copenhageni y mozdok. Vacci Monitor 10(3): 1-6.
23. Ido, Y,R. Hoki, H. Ito, and H. Wani. (1916). The prohylaxis of Weil's disease (Spirochaetosis icterohaemorrhagica). J Exp Med 24:471-483.
24. National Service of Animal Sanity. (2000). 309/2000 disposition. Ethical considerations for the use of laboratory animals (Document regulatory). Cuba: MINSAP. p. 215-232.
25. Reed, L.J, and H.A. Muench. (1938). Simple method of determining fifty percent endpoints. Am J Hyg 27:494-497.
26. Naranjo, M., Y. Rodríguez, R. Oliva, U. Jáuregui, and M. Gonzalez. (1999). Immunization outline in hamsters front the Cuban antileptospirosic prepared vacunal. Acta Farm Bonaerense 18:121-126.
27. Fajardo, E.M., B. Ortiz, A. Chávez, N. Gainza, L. Izquierdo, and Y Hernandez. (1998). Standardization the 50 lethal dose of Leptospira interrogans strains used in the control of the Cuban vaccine against the human leptospirosis. Cuban Journal of Tropical Medicine 50(1):22-26.
28. McBride, AJ., D.A. Athanazio, M.G. Reis, and A.I. Ko. (2005). Leptospirosis. Curr Opin Infect Dis 18(5):376-386.
29. Silva, E.F., M.A. Medeirosc, J.A. McBridea, J. Matsunagad, G.S. Esteves, and J.G. Ramos. (2007). The terminal portion of leptospiral immunoglobulin-like protein LigA confers protective immunity against lethal infection in the hamster model of leptospirosis. Vaccine 25(33):6277-6286.
30. Silva, E., C.S. Santos, D.A. Atanasio, N. Seyffert, F.K. Seixas, and G.M. (2008). Cerqueira. Characterization of virulence of Leptospira isolates in a hamster model. Vaccine 26: 3892-3896.
31. Levett, P.N. (2001). Leptospirosis. Clin Microbiol Rev 14(2):296-326.
32. ® Applied Biotecnology 21:77-81.
33. Faine, S., B. Adler, C. Bolin, and P. Perolat. (1999). Leptospira and Leptospirosis. 2nd ed Melbourne: Edit MediSci. p. 33-51.
34. Sonrier, C., C. Branger, V. Michel, N. Ruvoen-Clouet, J. Ganiere, and G. Andre-Fontaine. (2000). Evidence of cross-protection within Leptospira interrogans in an experimental model. Vaccine 19:86-94.
35. Staneck, J.L., R.C. Henneberry, and C.D. Cox. (1973). Growth requirements of pathogenic leptospires. Infect Immun 7(6):886-897.
36. Brown, R., S. Blumerman, C. Gay, C. Bolin, R. Duby, and C. Baldwin. (2003). Comparison of three different leptospiral vaccine for induction of a type 1 immune response to Leptospira borgpetersenii serovar Hardjo. Vaccine 21:4448-4458.
37. Naiman, B.M., S. Blumerman, D. Alt, C. Bolin, R. Brown, and R. Zuerner. (2002). Evaluation of type 1 immune response in naïve and vaccinated animal following challenge with Leptospira borgpetersenii serovar Hardjo: Involvement of WCI gdand CD4 cells. Infect Immun 70:6147-6157.
38. Chapman, A.J., C.O. Everard, S. Faine, and B. Adler. (1991). Antigens recognized by the human immune response to severe leptospirosis inBarbados. Epidemiol Infect 107:143-155.
39. Cinco, M., D. Delneri, and E. Banfi. (1992). Immunodominant antigens recognized by the human immune response to infection by organism of the species Leptospira interrogans serogroup Australis. FEEMS Microbiol Immunol 89:287-298.
40. Gitton, X., M.B. Daubié, F. André, J.P. Ganiére, and G. André-Fontaine. (1994). Recognition of Leptospira interrogans antigens by vaccinated or infected dogs. Vet Microbiol 41:87-97.